March 10, 2020 / 1:02 PM / a month ago

BRIEF-Bellerophon Announces FDA Agreement On Its Planned Pivotal Phase 3 Study For The Treatment Of Pulmonary Hypertension Associated With Pulmonary Fibrosis

March 10 (Reuters) - Bellerophon Therapeutics Inc:

* BELLEROPHON ANNOUNCES AGREEMENT WITH THE FDA ON ITS PLANNED PIVOTAL PHASE 3 STUDY FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS

* BELLEROPHON THERAPEUTICS INC - FINALIZED KEY ELEMENTS OF ITS PLANNED PIVOTAL PHASE 3 STUDY FOR TREATMENT OF PULMONARY HYPERTENSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below